Potse
4月前
ANAS...fourth roadshow, added to position.....
How to capitalize on the US stock market's super bull run? Entrepreneurs and investors are welcome to join me next Monday to discuss this!
Monday, February 2, 2026
• 1:00 – 1:30 2026 Nasdaq Listing Seminar – Speaker: Cai Yiqun
• 1:30 – 3:00 US Immigration (US Real Estate + Mortgage), St. Keejohn Immigration Explanation + Q&A
Roadshow
• 3:00 – 3:20 Yuanchuang Medical – Non-invasive Radiotherapy for Obesity and Diabetes
• 3:20 – 3:40 Zhongnongyuanfang Group – China's Leading Biochip Enterprise
• 3:40 – 4:00 Xingjizhou Intelligent Technology – Penetrating Vision – AI Intelligent Driving, Drones, Robots, Monitoring, and Other Applications
• 4:00 – 4:20 GTi – Beverage and Food Packaging, 100% Plant-Based Degradable Raw Materials, Compliant with EU PPWR Regulations (Online)
• 4:20 – 4:40 Akelos – US (Long-Term Pain) New Drug R&D – Star Team Three Harvard graduates and one Nobel laureate (online)
- MAS Capital Family Office:
Noah Fortune Center-B Room 201, 1226 Shenbin South Road, Minghang District, Shanghai, China
https://www.instagram.com/p/DUDA9kCgWbm/
Potse
5月前
ANAS...third roadshow event......
Added a few more shares to my position. The second roadshow event is being held on January 19. It is a combination of a Nasdaq listing seminar (Aaron Tsai will be the speaker), and roadshow events for ANAS and three other companies.....
The third roadshow event is January 20. This one is exclusively for this company and is being held in the city where Xi'an Lianer Technology is located......
Let's have a good meal before giving this afternoon's speech and roadshow!
How to capitalize on the US stock market's super bull run? Entrepreneurs and investors are welcome to discuss this with me!
• 2:00 – 2:30 2026 Nasdaq Listing Seminar – Speaker: Cai Yiqun
Roadshow Activities
China National Agricultural Park Group
Our Advantages
? Its subsidiary, Xi'an Lianer Technology, is the first high-tech enterprise in mainland China to be approved by the National Medical Products Administration (NMPA) to use biochips for clinical diagnosis.
? We have been deeply involved in the in vitro detection technology of medium and low density biological protein permeation wafers. Currently, we have a market share of up to 60% in this field in mainland China and have more than 1,000 end-user hospital customers.
? Independent intellectual property rights: 11 national patents (3 invention patents, 7 utility model patents, and 1 design patent) and 5 software copyrights.
? Multi-indicator test kits: tuberculosis pentavalent test, cervical cancer pentavalent test, prenatal and postnatal care pentavalent test, infertility hexavalent test, Helicobacter pylori test, respiratory tract hexavalent test, and Brucella quadrivalent test, etc., which are fast, accurate, and low-cost; all of them have been included in the medical insurance reimbursement items in mainland China.
January 20, 2026, 2:00 PM - 4:00 PM, Grand Hyatt Xi'an
https://www.facebook.com/kingofshells
Potse
5月前
ANAS...second roadshow event.....
I have been adding heavily to my position at these sub-2 cent prices. Current cost basis is under .0122, with about half those shares qualifying for long-term capital gains. Risk/reward looks interesting to me with potential catalysts approaching. According to Aaron Tsai's social media accounts (Instagram, X, Facebook), ANAS will be having its first pre-IPO private equity roadshow event next week (December 19).
Added a few more shares to my position. The second roadshow event is being held on January 19. It is a combination of a Nasdaq listing seminar (Aaron Tsai will be the speaker), and roadshow events for ANAS and three other companies.....
How to master the super bull market in beauty stocks? Entrepreneurs and investors are welcome to discuss with me tomorrow!
19 January 2026
• 12:00 – 12:30 2026 Nasdaq listing seminar – Speaker by Yiqun Tsai
Roadshow event
• 12:30 – 1:00 Yuan Chuang Medical - Noninvasive Radiotherapy for obesity and diabetes
• 1:00 – 1:20 Starboat Smart Technology - Perseverance Vision - AI intelligent driving, drones, robotics, surveillance, etc.
• 1:20 – 1:40 GTi - Beverage, food packaging, 100% plant detachable ingredients, EU PPWR regulations (online)
• 2:00 – 4:00 Zhongnong Garden Group - China's leading biochip company
https://www.instagram.com/p/DTpAHWXASPl/
https://www.instagram.com/p/DTpb-KmgSG0/
Potse
5月前
Stonewallet...reverse split possibility......
Really like the existing share structure, with only an 11 million share float. However, considering this share structure in combination with the news of ANAS bringing in MAS to facilitate an uplisting, wouldn't a R/S be the likely vehicle used to get the SP up to those levels....barring the release of some terrific announcement or financials, of course? That would certainly damper any enthusiasm. After many years of doing this, I've yet to see a R/S benefit my portfolio in the long run.
A reverse split on this stock is highly likely at some point. Nobody likes to see reverse splits, but is an almost unavoidable fact of life when dealing with shells, reverse mergers, or already-operating companies that are seeking to uplist to a higher exchange. Of the shells and operating companies I currently own, very few of them have a realistic chance at qualifying for an uplisting without the assistance of a reverse split.
So if I allow my dislike/fear of reverse splits to completely dominate my buying decisions, I am going to be left with a very small pool of stocks from which I can select. Plenty of shells or operating companies with less-than-ideal share structures and/or red flags manage to go on very nice runs. So if I limit my purchases to only the most perfect of situations, I am probably going to miss some pretty nice opportunities.
I don't know if this stock will turn out to be one of those opportunities, but I am willing to take a chance and find out. There are obvious catalysts approaching (good or bad), and market awareness of this stock is still relatively low. Should be interesting to see what happens.
Stonewallet
5月前
Good information, thanks. I have established a decently-strong starter position here at these price levels. Really like the existing share structure, with only an 11 million share float. However, considering this share structure in combination with the news of ANAS bringing in MAS to facilitate an uplisting, wouldn't a R/S be the likely vehicle used to get the SP up to those levels....barring the release of some terrific announcement or financials, of course? That would certainly damper any enthusiasm. After many years of doing this, I've yet to see a R/S benefit my portfolio in the long run.
Potse
6月前
ANAS...pre-IPO private equity roadshow.....
I have been adding heavily to my position at these sub-2 cent prices. Current cost basis is under .0122, with about half those shares qualifying for long-term capital gains. Risk/reward looks interesting to me with potential catalysts approaching. According to Aaron Tsai's social media accounts (Instagram, X, Facebook), ANAS will be having its first pre-IPO private equity roadshow event next week (December 19). Translation of the graphic that accompanies his posts......
Its subsidiary, "Xi'an Lian'er Technology," is the first high-tech enterprise in mainland China to be approved by the National Medical Products Administration (NMPA) for using biochips in clinical diagnostics.
Deeply involved in medium-to-low-density protein biofiltration chip technology, currently holding a market share of up to 60% in this field in mainland China, with over 1,000 terminal hospital clients.
Independent intellectual property rights: 11 national patents (3 invention patents, 7 utility model patents, 1 design patent) and 5 software copyrights.
Tuberculosis urine screening reagent: The only product in mainland China and globally that can rapidly detect the LAM antigen, possessing huge potential for development into a home self-testing market.
Multi-indicator combined testing reagents: Such as cervical cancer five-in-one test, eugenics five-in-one test, infertility six-in-one test, Helicobacter pylori test, respiratory seven-in-one test, and brucellosis four-in-one test, all of which are fast, accurate, low-cost, and have been included in mainland China's medical insurance coverage.
https://www.instagram.com/p/DR4Cy44AdcN/
中农园方集团2026赴纳斯达克IPO前私募路演,第一场将在新北市举办! pic.twitter.com/R05QMD8Orv— Aaron Tsai (@AaronTsaiMASFi) December 5, 2025
Potse
6月前
ANAS...MAS Capital, Nasdaq uplisting......
First news item on the company website since March 2022......
Alternaturals, Inc. Partners with MAS Capital to Officially Launch NASDAQ Uplisting Plan
2025-11-20
Alternaturals, Inc. (OTC: ANAS) ("Alternaturals" or the "Company"), a US OTC-listed company, announced today that it officially signed a financial services agreement with the internationally renowned financial advisory firm MAS Capital (CI) Inc. ("MAS Capital") on November 17, 2025. Under the agreement, MAS Capital will serve as the Company's exclusive financial advisor, providing comprehensive capital market consulting to fully guide the Company in its transition (uplisting) from the OTC market to the NASDAQ main board.
Founded in 1995, Alternaturals, Inc. is headquartered in Reno, Nevada, USA, with its administrative office located in Xinzhuang District, New Taipei City, Taiwan. In recent years, the Group has successfully integrated multiple enterprises through a precise M&A strategy, including Hong Kong UR Development Group, Beijing Zhongnong Yuanfang Technology, Xi'an Lian-er Technology, Xi'an Lian-er Biotechnology, Chongqing Lian-er-mei Biotechnology, and Xi'an Hua-hui Biotechnology. The Company is committed to introducing cutting-edge technologies such as AI (Artificial Intelligence), IoT (Internet of Things), and Big Data into the biotechnology industry, building a highly competitive group-oriented operational system.
The core objective of this IPO plan is to list on NASDAQ. The Company expects to raise US$25 million and aims to complete the listing between the third and fourth quarters of 2026. The goal is to leverage the power of capital markets to accelerate the expansion of AI biotechnology applications and drive innovation and integration within the general health industry chain.
MAS Capital was founded in 1995 by the renowned Chinese-American investment banker Mr. Aaron Tsai. Its international division specializes in assisting Asian enterprises to list in the United States. As a member of the National Investment Banking Association (NIBA), the firm possesses extensive experience in cross-border capital operations and has successfully guided 101 companies to public listing to date.
Through this strategic cooperation, Alternaturals, Inc. will leverage MAS Capital's deep resources and professional planning capabilities in both US and Chinese capital markets to accelerate the uplisting process. This marks not only a key milestone in the Group's global layout but also aims to translate leading AI biotech technologies into substantial commercial value, creating long-term and robust investment returns for shareholders.
https://znyfinc.com/en/news/display/16